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Abstract: Unlike microbes that infect the human body, cancer cells are descended from normal cells
and are not easily recognizable as “foreign” by the immune system of the host. However, if the
malignant cells can be specifically earmarked for attack by a synthetic “designator”, the powerful
effector mechanisms of the immune response can be conscripted to treat cancer. To implement this
strategy, we have been developing aptamer-derived molecular adaptors to invoke synthetic immune
responses against cancer cells. Here we describe multi-valent aptamers that simultaneously bind
target molecules on the surface of cancer cells and an activated complement protein, which would tag
the target molecules and their associated cells as “foreign” and trigger multiple effector mechanisms.
Increased deposition of the complement proteins on the surface of cancer cells via aptamer binding
to membrane targets could induce the formation of the membrane attack complex or cytotoxic
degranulation by phagocytes and natural killer cells, thereby causing irreversible destruction of the
targeted cells. Specifically, we designed and constructed a bi-functional aptamer linking EGFR and
C3b/iC3b, and used it in a cell-based assay to cause lysis of MDA-MB-231 and BT-20 breast cancer
cells, with either human or mouse serum as the source of complement factors.
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1. Introduction
In cancer therapy, the preferred targets are cancer cells rather than individual molecules,
and the preferred outcome is irreversible destruction rather than reversible neutralization.
Many approaches to cancer treatment, including the binding of inhibitors to active protein
sites, can only reversibly neutralize targets at the molecular level. However, at the cellular
level, when appropriate markers are available, they may be utilized for targeting and
destruction of specific cell types, which is a more powerful strategy for the eradication of
cancer cells. Unlike infectious microbes, cancer cells are descendants of normal cells, not
easily recognizable as “foreign” by the immune system of the host. If the malignant cells can
be specifically earmarked by a synthetic “designator”, the powerful effector mechanisms
of the immune response may be recruited to treat cancer. This approach is conceptually
analogous to targeted drug delivery, but the “drugs” being delivered are patient- or hostderived factors and cells that are able to put on a powerful immune response with higher
specificity and fewer side effects.
In the human complement system, C3 is a key component of innate immunity, as
in all pathways of complement activation the pivotal step is the conversion of C3 to
C3b [1]. Complement has two major effector mechanisms for host defense, formation of
the membrane attack complex (MAC), and opsonization. The MAC generated from C5-C9
can form membrane-penetrating lesions that lead to cell death by causing a rapid loss of
cytoplasmic components [2]. Opsonization is the process by which particles become coated
with molecules (opsonins) that allow them to bind to receptors on effector cells such as
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macrophages or NK cells [3]. The most important opsonins are antibodies and complement
proteins including C3b/iC3b. Phagocytosis and cytotoxic degranulation are initiated by
the interaction of specific receptors for the opsonins on the surface of the effector cells [4,5].
Because MAC formation and cytotoxicity are powerful ways of eliminating harmful
cells, it would be desirable to re-direct these mechanisms for cancer treatment. This idea was
proposed more than 30 years ago [6], and it has come into play recently with great potential
as an effector system [7,8]. Complement has a number of advantages because its molecules
can easily penetrate the tumor mass, and several of them can be supplied by nearby cells [7].
C3b/iC3b is constitutively available as part of the alternative pathway of complement
activation through spontaneous hydrolysis (“tick over”) of C3 [9]. However, due to the
nature of its linkage with the particles it tags, C3b/iC3b is less specific as an adaptor
compared to antibodies [10]. Instead of specific non-covalent interaction, C3b/iC3b uses
a thioester as its “warhead” for covalent attachment to the particle being opsonized [11].
Although C3b shows a preference for certain hydroxyl groups, it lacks an intrinsic ability
to distinguish self from non-self, and only 10% of activated C3b molecules become linked
to antigenic surfaces [1].
We propose to equip C3b/iC3b with a synthetic adaptor that provides high specificity
and efficiency, enabling us to intentionally tag unwanted “self” cells as “foreign” to elicit
a response against them. In this configuration, the C3b/iC3b molecule and the adaptor
molecule together would function as a synthetic designator with specificity and efficiency
comparable to that of antibodies. We envision this molecular adaptor for C3b/iC3b as a
composite bi-functional aptamer in the form of modified RNA. To implement this strategy,
we attempted to coat cancer cells with the opsonin C3b/iC3b via their surface markers
linked to molecular connectors derived from aptamers. Once associated with the cell surface, we hypothesized that C3b/iC3b would recruit effector factors or cells to the vicinity
of the target cells and activate them to form MACs or perform cytotoxic degranulation. Previously, we established the concept of “aptamer-mediated opsonization” by demonstrating
specific degradation of a molecular target, using C3b/iC3b to direct uptake of the target by
cell surface receptors [12]. In this report, we now describe selective tumor cell lysis enabled
by bi-functional aptamers connecting C3 derivatives with a cell surface marker.
2. Materials and Methods
2.1. Proteins, Sera, Antibodies, Oligonucleotides, and Cells
Purified human complement proteins C3, C3b, and iC3b were purchased from Quidel
Corp (San Diego, CA, USA). Recombinant EGFR-Fc was from R&D Systems (Minneapolis,
MN, USA). Human serum and mouse serum were from MilliporeSigma (Burlington, MA,
USA), fetal bovine serum (FBS) was from Atlanta Biologicals (now R&D Systems), and horse
serum (heat inactivated, New Zealand origin) was from Thermo Fisher Scientific (Waltham,
MA, USA). Anti-EGFR monoclonal antibody sc-101 was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-C3c was from Quidel, and anti-mouse Alexa Fluor 594 from
Invitrogen (Waltham, MA, USA). Streptavidin-phycoerythrin (SA-PE) was purchased from
Molecular Probes (Eugene, OR, USA). All oligonucleotides were synthesized by Integrated
DNA Technologies (Coralville, IA, USA).
Cell lines: MDA-MB-231and BT-20 cells were received from ATCC, and grown in
RPMI-1640 medium supplemented with 10% FBS and antibiotic. MCF-10A cells were a
kind gift from Dr. J. I. Herschkowitz (Department of Biomedical Sciences, School of Public
Health, University at Albany, Albany, NY, USA) and were grown in DMEM supplemented
with 5% horse serum, 5 µg/mL insulin, 1 µg/mL hydrocortisone, 100 ng/mL cholera toxin,
100 µg/mL EGF and antibiotic. All cells were incubated at 37 ◦ C with 5% CO2 .
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2.2. Nucleic Acid Sequences
Sequence of the isolated aptamers:
AptC3-I:
50 -GGGAGAAUUCAACUGCCAUCUAGCUACAAAAAUACGAGGAAAGC
AAAGUACCAGUGUAGCUACCAAAAGGAGUAGUAAAACACUACAAGC
UUCUGGACAUCGGU-30
AptC3-II:
50 -GGGAGAAUUCAACUGCCAUCUAGCUUGACCAAUAAGACGUAUUG
GCCUCCUACGCAUGGCAAGCAGUUCUCUCUACUGAACUACAAGCUU
CUGGACUCGGU-30
AptC3-III:
50 -GGGAGAAUUCAACUGCCAUCUACAGCCCCUCGGCCGCGUUCAGCG
UCUAACCUUGGGCUGUAUAGAAAGGGUUUCCAGACUACAAGCUUCU
GGACUCGGU-30
AptC3-IV:
50 -GGGAGAAUUCAACUGCCAUCUAGUUGCAAAAACAUGAGGAUAGC
AAAGUACCAGUGCAACUAACAAGGAAAAGAAGACGGACUACAAGCU
UCUGGACUCGGU-30
APTC3-V:
50 -GGGAGAAUUCAACUGCCAUCUAGCUACGUGGAACCUAAGGUUAA
ACCGUAUGAUGCAGUUGUACACUCCAAACGAAGAACUACAAGCUUC
UGGACUCGGU-30
AptC3-VI:
50 -GGGAGAAUUCAACUGCCAUCUAACCACGUAGUAAUACGGUAUGA
UCCAGUUUUAAUUCUAACCAGACUGUUCAGAUGACUACAAGCUUCU
GGACUCGGU-30
Sequence of miniE07 with extension (E07s-e):
50 -GGGACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCGGAAC
CGUCCCGAAUUAAAUGCCCGCCAUGACCAG-30
Its biotinylated complementary DNA oligo:
50 biotin-CTGGTCATGGCGGGCATTTAATTC-30
Sequences used to assemble the Tri-molecular and bi-molecular versions of “Trifecta”:
The tri-molecular construct (Trifecta-t) was assembled from the following three fragments.
Ft1 (miniE07 + a3WJ ):
50 -GGGACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCGGAAC
CGUCCCUUGCCAUGUGUAUGUGGG-30
Ft2 (miniAptC3-III + c3WJ ):
50 -GGGCCCCUCGGCCGCGUUCAGCGUCUAACCUUGGGCCCGGAUCAA
UCAUGGCAA-30
Ft3 (b3WJ ):
50 -CCCACAUACUUUGUUGAUCC-30 [This is a DNA oligo with U instead of T.]
The bi-molecular construct (Trifecta-b) was assembled from two fragments, Fb1 and
Fb2.
Fb1 (miniE07 + a3WJ ):
50 -GGGACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCGGAAC
CGUCCCUUGCCAUGUGUAUGUGGGCCC-30
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Fb2 (b3WJ + miniAptC3-III + c3WJ ):
50 -GGGCCCACAUACUUUGUUGAUCCGGGCCCCUCGGCCGCGUUCAGC
GUCUAACCUUGGGCCCGGAUCAAUCAUGGCAA-30
Sequence of mutated AptEGFR domain and AptC3 domain in the Trifecta derivatives:
Mut-miniE07:
50 -GGGUCGUGGCGCGAGCUGAUAAAUACAUGCCCAUAUUAAGGAAC
CGUCCC-30
Mut-AptC3-III:
50 -GGGCUCCUGGUCGCCGUCCAGGCUCUACACGUCGCGGC-30
2.3. In Vitro Selection
The procedures of pool construction and selection/amplification were modified from
those published before [12,13] and described in detail in the Appendix A. Selected DNA
pools were cloned in the pSTBlue-1 vector (Novagen, St. Louis, MO, USA) using a Perfectly
Blunt Cloning Kit (Novagen). Ligated plasmid was transformed into NovaBlue Singles
competent cells (Novagen). Plasmid DNA bearing inserts was purified for sequencing.
For each selection at least 50 clones were sequenced and analyzed for characterization.
Sequencing was performed in the Life Sciences Instrument Core Facility of the University
at Albany. Minimization of aptamers was performed using deletion analysis.
2.4. Molecular Binding Assays
Electrophoretic mobility shift assay (EMSA) and filter binding assay were performed
as described in [12]. A typical binding mixture with 32 P-labeled RNA contained about
~20 fmol of the RNA probe and different amounts of protein (at least 1 pmol) in 20-µL
volumes. In competition assays, the competing unlabeled RNA was in excess of protein by
at least 10 folds, and both labeled and unlabeled RNA’s were presented to the protein target
simultaneously. The binding buffer contained 20 mM HEPES, (pH 7.4), 150 mM NaCl,
and 10 mM MgCl2 . Both BSA and yeast RNA at 1 µg/20 µL were added to the binding
reaction to prevent nonspecific binding. The binding mixtures were incubated for 45 min at
37 ◦ C before being subjected to filter-binding or electrophoresis. Filter-binding assays were
performed with nitrocellulose filters (MilliporeSigma, Burlington, MA, USA) and a Bio-Dot
SF (slot format) Microfiltration System (Bio-Rad, Hercules, CA, USA). Specific conditions
for individual experiments, such as gel concentration and buffer type, are given in figure
legends.
2.5. Assembly of Multi-Valent Aptamers
Subcloned or PCR-generated double strand DNA templates were transcribed in vitro
using the DuraScribe T7 transcription kit (Epicentre/Lucigen, Madison, WI, USA) to generate individual aptamers. To assemble bi-functional aptamers all three or two components
were mixed at equimolar ratio in 1x binding buffer (20 mM HEPES, 150 mM NaCl and
10 mM MgCl2 , pH 7.4). The solution was heated at 95 ◦ C for 2 min and then slowly
cooled to room temperature over 1 h [14]. The mixture was electrophoresed in an 8%
native polyacrylamide gel (acrylamide:bis-acrylamide = 37.5:1) in buffer (45 mM Tris base,
54 mM boric acid, and 2.5 mM MgCl2 ). Correctly assembled products were purified from
the gel and passed through a Sephadex G-50 spin column. Concentration was measured
spectrophotometrically.
2.6. Aptamer Stability Assays
The stability of assembly was measured by incubating the “Trifecta” in 1x binding
buffer with 0, 2, 4, 6, or 8 M urea for 30 min at 37 ◦ C, followed by electrophoresis in an
8% native acrylamide gel in 1/2 x TBE buffer. One oligo of the complex was radiolabeled.
After electrophoresis the gel was exposed to phosphor screen and scanned by a Storm
phosporimager (GE Healthcare, Chicago, IL, USA).
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2.7. Cell Surface Binding Assays
MDA-MB-231 cells were seeded in 8-well chamber slides at ~3500 cells/well and
grown in 10% FBS for 48 h. Cells were washed 3 times with PBS and fixed 10 min in 4%
paraformaldehyde in PBS, then washed again 3 times with PBS.
EGFR Detection: Nonspecific binding was blocked by incubating the cells for 30 min
in PBS containing 1% BSA. Wells were washed 3 times with 0.5 mL PBS, and cells were
incubated with a 1:200 dilution of anti-EGFR monoclonal antibody sc-101 in PBS for 1 h.
Cells were then washed extensively and incubated with 1:200 anti-mouse Alexa Fluor 594
for 1 h, washed again, and coverslipped in 1:500 DAPI/glycerol diluted 1:1 with PBS. Slides
were photographed under a microscope at 44 ms (for DAPI) and 118 ms (for Alexa Fluor
594) exposures.
Detection of Anti-EGFR Aptamer: Cells were first blocked with Biotin/Avidin blocking
solutions (Molecular Probes) following the manufacturer’s directions. To block nonspecific
binding of nucleic acids, cells were incubated in 5x Denhardt’s solution for 20 min, then
washed 3 times in PBS and blocked again with 0.13 µg/µL BSA and 0.17 µg/µL torula
yeast RNA in PBS containing 5 mM MgCl2 for 20 min. Anti-EGFR aptamers or control 2’-F
Py RNA (at a final concentration of 2.64 µM) were mixed with biotinylated oligonucleotide
and denatured by heating 5 min at 70 ◦ C in 100 µL of binding buffer (PBS containing 10 mM
MgCl2 ) and cooled to 25 ◦ C at 1 ◦ C/sec. Then, 7 µL of SA-PE was added, and the mixtures
were incubated for 15 min at 25 ◦ C and pipetted to wells containing 100 µL of binding
buffer, 0.13 µg/µL BSA and 0.17 µg/µL yeast RNA, and incubated for 15 min. Finally, cells
were washed 4 times in 500 µL binding buffer and coverslipped in 1:500 DAPI/glycerol
diluted 1:1 with binding buffer. Slides were photographed under a microscope at 82 ms
(DAPI) and 300 ms (SA-PE) exposures.
Detection of C3c-containing complement molecules: Nonspecific binding of protein
to cells was blocked by incubating cells in 0.1 µg/µL BSA in binding buffer overnight.
Nonspecific binding of nucleic acids was blocked by incubating cells in 0.75 µg/100 µL
poly DI/DC in binding buffer overnight, followed by incubation in 5x Denhardt’s solution
for 20 min, then washing 3 times in PBS and blocking again with 0.13 µg/µL BSA and
0.17 µg/µL torula yeast RNA in binding buffer for 20 min. Bi-functional aptamer (“Trifecta”)
or control 2’-F Py RNA in binding buffer was divided between wells at a final concentration
of 0.25 µg of each aptamer per well. Cells were incubated with RNA for 45 min and washed
gently 2 times in binding buffer. Then 10% human serum in 100 µL of binding buffer was
added to wells and cells were incubated for 45 min. Cells were washed gently twice in
binding buffer, then 1:250 anti-C3c was added to all but the “no-primary antibody” control
well, and incubated for 45 min. (The primary antibody was previously adsorbed to cells
to reduce background.) Cells were washed 4 times with binding buffer and incubated
with 1:250 anti-mouse Alexa Fluor 594 in 100 µL of binding buffer for 45 min, then washed
4 times gently and coverslipped in 1:500 DAPI-glycerol diluted 1:1 in binding buffer.
2.8. Cell Viability Assays
Mid-log phase cells were trypsinized and seeded at ~3000 cells/well of a 96-well
tissue culture plate. Cells were allowed to grow for 12 h, followed by incubation with 1
µM “Trifecta” or its mutated variants in a medium containing 25% human serum. Fresh
RNA-containing medium was replenished every 24 h for three days.
Cells were then washed with 200 µL 1x PBS two times, and fixed with 10% formalin
solution for five min. Fixed cells were washed once with 200 µL water and stained with
100 µL 0.2% crystal violet solution for half an hour. Stained cells were washed three times
with 200 µL water. Bound dye was eluted for 30 min with 100 µL 0.1% SDS solution in
water. All incubations were carried out at room temperature. The concentration of eluted
dye was determined by reading absorption at 540 nm with a multiplate reader (BioTek
SynergyH1, Agilent, Santa Clara, CA, USA). Numbers of viable cells were determined
using a standard curve. For experiments with mouse serum, cells were treated as described
above, except that 25% mouse serum was used in the medium. Cells were photographed
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These aptamers would be used as utility aptamers in the bi-functional molecular adaptors. To investigate the binding affinity and specificity of the six aptamers, electrophoretic
mobility shift assays (EMSA) and filter binding assays with radioactively labeled full-length
RNA aptamers were performed. The dissociation constants of these aptamers are in the
range of 10–60 nM. As an example, the Kd of the aptamer AptC3-III (which was chosen
later for cell viability assays) was 17 nM for C3, and 14.5 nM for iC3b (Figure 2A). Affinities
of the other aptamers are summarized in Table A1 of the Appendix A.
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Figure 2. Characterization of C3 aptamers. (A) Affinity of AptC3-III as measured by filter binding.
Values represent the average of three independent assays. Error bars indicate standard deviations.
The dissociation constant is 17 nM for C3 and 14.5 nM and for iC3b. (B) Competition between
AptC3-II and AptC3-III as measured in a filter binding assay. The protein concentration was 50 nM.
The unlabeled (cold) RNA used was 3 µM. In addition, 1 µM yeast genomic RNA and 1 µM BSA were
used in all reactions. (C) Different preference of binding to C3 and its derivatives by the aptamers.
An EMSA gel, 5% native polyacrylamide with acrylamide:bis-acylamide = 70:1, run in 1/2 x TGB
buffer (12.5 mM Tris, 100 mM glycine) with 2.5 mM MgCl2 , is shown, in which 250 nM protein was
used to reveal the shifted bands. (D) Affinity to mouse orthologs. An EMSA gel (conditions are same
as in C) is shown. Two microliters of mouse serum was used in each reaction and the incubation
time was 30 min. M. S. = Mouse Serum. In all panels, names of aptamers are abbreviated (e.g.,
Apt-I = AptC3-I).
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The aptamers were further characterized by competition assays to determine whether
any aptamers are mutual competitors, presumably for a single target site. We found that
AptC3-II and AptC3-III are mutually competitive (Figure 2B): thus, there seem to be five
distinct classes of aptamers that bind to different sites on C3 and/or its proteolytic products.
To investigate their different target preference among C3, C3b, or iC3b, we performed
EMSA. As shown in Figure 2C,D, most of the aptamers were able to recognize all three
proteins, whereas AptC3-VI shows greater specificity toward C3b and AptC3-IV toward
C3b and iC3b.
Additionally, we performed deletion analysis to define minimized portable versions
that can be more efficiently incorporated into the bi-functional constructs. The full-length
sequence of each aptamer was progressively and successively deleted 5-nt at a time from
either end until the activity was lost. Then deletions less than 5-nt were tested to refine
the border. These shorter sequences were tested by EMSA under the condition identical to
that presented in Figure 2C, and the results are indicated by the underlined sequences in
Figure 1. Except for AptC3-I, all aptamers yielded active shorter forms ranging from 37 nt
to 64 nt with an average length of 45 nt. Except the one derived from the AptC3-III, these
minimized sequences all include a portion of the 5’ conserved region.
Importantly, although they were selected against human targets, these aptamers were
able to bind mouse orthologs equally well. Mouse and human C3, C3b and iC3b have 77%
identity and 88% positive residues (with matching charges) based on BLASTp alignments.
In EMSA, when the purified human complement proteins were replaced by mouse serum,
all aptamers formed a retarded complex with similar mobility to the complexes generated
by purified human proteins. In Figure 2D, results for three different aptamers are given as
examples. This human-mouse portability would facilitate the future use of these aptamers
in animal models.
3.2. Adaptation of a Targeting Aptamer
Epidermal growth factor receptor (EGFR) is a tyrosine protein kinase and a cell surface
glycoprotein implicated in epithelial tumorigenesis [15]. Binding of epidermal growth
factor to its receptor triggers EGFR autophosphorylation and drives a complex intracellular
signal transduction pathway, which modulates a set of cancer-related phenotypes. EGFR
has been used as a tumor biomarker and a drug target for monoclonal antibodies (e.g.,
cetuximab and panitumumab) and low-molecular weight tyrosine kinase inhibitors (e.g.,
gefitinib and erlotinib). An anti-EGFR aptamer, E07, has been isolated in the form of
2’-F Py RNA [16], and we modified this aptamer for use as the targeting aptamer in the
bi-functional constructs to connect a target cell to the complement system.
MDA-MB-231 cell line was used as our first cellular target. This cell line demonstrates
an invasive phenotype and high metastatic potential. It expresses EGFR on its surface, and
resembles the Claudin-low subtype of triple-negative breast cancer (TNBC) [17,18]. The
majority of TNBCs (>50%) are EGFR positive, yet individual tumor cells frequently display
or develop resistance to EGFR inhibitors [19,20], and clinical trials of EGFR inhibitors
in TNBC have been disappointing [21]. Our method employs a mechanism different
from solely inhibiting EGFR activity, which might function in resistant tumors that retain
membrane EGFR.
The E07 aptamer is 93-nt in length. Before incorporating E07 into a bi-functional
construct, we created a minimized version, miniE07, and investigated its binding to the
MDA-MB-231 cell surface. Using an anti-EGFR antibody, we confirmed the expression
of EGFR on MDA-MB-231 breast cancer cells (Figure 3A). To detect the EGFR aptamer,
we added a 24-nt extension to the 50-nt miniE07 to allow for association of a biotinlabeled complementary DNA oligonucleotide with binding of SA-PE to biotin as the
signal in fluorescence microscopy. We confirmed binding of this 74-nt version to human
EGFR protein by EMSA and filter binding assay using recombinant EGFR-Fc, a 190.2 kDa
disulfide-bonded homodimer containing residues 25–645 of human EGFR and residues
100–330 of Fc (Figure 3B). A mutant version of miniE07 (see Materials and Methods for
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3.3. Construction of Bi-Functional Aptamers
Construction of multivalent aptamers requires correct folding of each individual
aptamer in the composite. Simultaneous binding of two or more targets to a multivalent
construct may be prevented by steric hindrance. These two issues necessitate the testing of
multiple molecular designs. To facilitate quick and easy swap of individual aptamers to
generate alternative configurations, we used a non-covalent three-way junction (3WJ) to
articulate the aptamers. The 3WJ domain of phi29 pRNA [14] has been used as a scaffold to
connect different functional elements. Utilizing this system, each aptamer was synthesized
individually with a tail that forms one strand of the 3WJ and assembled in vitro.
We made more than a dozen constructs to pair the EGFR aptamer with each of the
six aptamers for C3 and its derivatives. These constructs were screened for simultaneous
binding to the target molecule (EGFR) and a utility molecule (iC3b). We chose iC3b to
represent the utility molecules because it comprises the majority of C3 derived opsonins
in vivo. Among different configurations tested, one outperformed the rest in triple complex
formation and was nicknamed “Trifecta”. It contains AptC3-III, which has the highest
affinity and the shortest portable sequence among the six. Secondary structures of the bivalent “Trifecta” in two slightly different forms are depicted in Figure 4A. In both constructs,
miniE07 and miniAptC3-III were placed, respectively, as the extension of H1 and H3 helices
of the 3WJ [14].
We first used a tri-molecular version to examine molecular binding in EMSA. In this
construct the a strand of the 3WJ was attached to the 3’ end of miniE07, the c strand of
the 3WJ was attached to the 3’ end of the minimized AptC3-III aptamer, and a DNA oligo
was used for the b strand of the 3WJ. This b-3WJ oligo enabled us to label the trimolecular
construct and establish the binding ability of each aptamer domain in EMSA to demonstrate
triple complex formation (Figure 4B). Subsequently, for cell-based assays, we made the bimolecular construct by covalently connecting the b-3WJ to AptC3-III. Three G’s were added
at the 5’ end of one strand to enable efficient transcription by the polymerase, and three C’s
were added at the 3’ end of the other strand to pair with them. These extra-nucleotides did
not result in significant difference in terms of binding activity between the two constructs
(Figure 4B).
The stability of the non-covalently articulated constructs was tested against both
strand dissociation and strand degradation. The stability of assembly was measured by
incubating either “Trifecta” in 0, 2, 4, 6, and 8 M urea for 30 min at 37 ◦ C followed by
electrophoresis in a native gel (Figure 4C). Because these aptamers will be used in the
extracellular environment, we also confirmed their stability in the presence of RNase. As
shown in Figure 4D, we did not observe significant degradation even after 72 h incubation
in 50% FBS.
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3.4. Deposition of C3 Family Proteins on the Target Cell Surface
Many of the cell surface proteins that can be used as molecular targets are receptors
that undergo ligand-induced internalization [22,23], prompting a question regarding the
feasibility of our general strategy. EGFR is a representative in this category, and the choice
of E07 as the target aptamer in our bi-valent constructs helped us investigate whether the
opsonin-aptamer-target complex could remain on the cell surface for sufficient time to
trigger downstream effects. E07 is known to be internalized into EGFR-expressing cells [16].
When A431 cells were incubated with E07 at 37 ◦ C for 30 min, about 23% of E07 was
internalized [16]. In contrast, 70 % of EGF was internalized in 15 min [24], indicating that
most of the aptamer could be retained on the cell surface long enough to recruit the effector
mechanism. However, before testing “Trifecta” on living cells we used immunochemical
methods with fixed cells to visualize C3 and its derivatives recruited to the surface of
MDA-MB-231 cells (because most fluorescent dyes are toxic to living cells).
Specifically, after the cells were fixed, nonspecific binding of protein and nucleic acids
were blocked with BSA, poly DI/DC, and yeast RNA. Bi-functional aptamer in binding
buffer was added at a final concentration of 2.64 µM (see Materials and Methods for more
details). For control wells, an equal amount of unselected 2’-F RNA pool was added to
the same final concentration. Other controls included no RNA, no added serum, and no
primary antibody. Cells were incubated with RNA for 45 min and washed. Then 10%
human serum in 100 µL of binding buffer was added to wells and cells were incubated
for 45 min. Cells were washed, and 1:250 anti-C3c was added to all but the “no-primary
antibody” control well, and incubated for 45 min. The anti-C3c antibody recognizes C3 and
all breakdown fragments containing C3c, including C3b and iC3b. Any of these breakdown
fragments could act as opsonins [1]. With the help of a secondary antibody, we observed
strong signals for C3 family proteins in the presence of bi-functional aptamer constructs
(Figure 5A) compared to the controls (Figure 5B,C). This result indicates that simultaneous
adaptor
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C3b/iC3b deposited on tumor cells may cause MAC formation or promote adhesion
of effector cells such as macrophages and NK cells through complement receptors,
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3.5. Reduced Viability of Target Cells
C3b/iC3b deposited on tumor cells may cause MAC formation or promote adhesion
of effector cells such as macrophages and NK cells through complement receptors, whereby
cytotoxicity may ensue. After demonstrating the aptamer-dependent surface deposition
of opsonins, we set up an assay with serum to see whether target cell viability could be
reduced. In this system only one effector mechanism, MAC formation, could be enacted, as
all factors required for MAC formation are present in serum whereas cell-mediated effects
such as CR3-dependent cellular cytotoxicity (CR3-DCC) requires additional signals or cells.
A major concern is the presence on tumor cells of inhibitory membrane-bound complement
regulatory proteins (mCRPs) such as CD46, CD55, and CD59, which enable cancer cells to
evade complement attack [25,26]. MDA-MB-231 cells are reported to have high expression
of both CD55 and CD59 [27,28], therefore serving as an informative target for evaluating
our approach.
Based on the bi-strand “Trifecta” (Trifecta-b), we constructed three derivatives as
controls: a double-aptamer mutant (mEGFR-mC3) in which both C3 and EGFR aptamers
were inactivated, and two single-aptamer mutants (EGFR-mC3 and mEGFR-C3). In cell
viability assays the cells were incubated with 1 µM “Trifecta” or other constructs in medium
containing 25% human serum. Fresh medium containing Trifecta-b or one of its derivatives
was replenished every 24 h for three days. Then cell viability was assayed using crystal
violet assays. When MDA-MB-231 cells were treated with these four constructs, we observed a 30–40% Trifecta-dependent reduction in viability (Figure 6A). Although the EGFR
aptamer reportedly inhibits proliferation and induces apoptosis of cancer cells [16], these
mechanisms require more than 10 days to reveal their effects.
To corroborate these results, we performed the same assay with two more cell lines,
BT-20 and MCF-10A. BT-20 is another breast cancer cell line known to express EGFR at a
high level. When BT-20 was used in place of MDA-MB-231, we observed a similar level of
cell lysis (Figure 6B). In contrast, MCF-10A, a non-tumorigenic mammary epithelial cell
line, has a very low level of EGFR expression. We did not observe any loss of viability of
MCF-10A cells in the presence of “Trifecta” (Figure 6C).
To further demonstrate the requirement of complement in these assays we performed
another experiment. Some critical factors in the complement activation pathway are known
to be sensitive to high temperature. Incubation of the serum at 56 ◦ C for 30 min has been
routinely used for complement inactivation [29]. When we used heat-treated serum in the
cell viability assays (indicated by an asterisk in Figure 6A–C), Trifecta-dependent cell lysis
was abolished, and cell viability was the same with all four constructs. Interestingly, similar
results were obtained when mouse serum was used in place of human serum, indicating
that the aptamer for C3b/iC3b interacts equally well with mouse complement. This is
consistent with the results of our binding assays (Figure 1D). Microscopically, disintegrating
cells were observed within 24 h of incubation (Figure 6D).
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However, for several reasons the observed cytotoxic efficacy of the bi-functional
aptameric construct only delineates the lower bound of its potency. First, these results were
obtained from a single molecular configuration. Different spatial arrangement and different
relative valency of the two aptamers may yield a more potent construct. Second, only one
effector mechanism, the formation of MAC, could be enacted in this preliminary study
because no effector cells were provided to carry out other cytotoxic mechanisms. Third,
many of the plasma complement factors are precipitated out during blood clotting and
therefore are not present in serum, and conversion of inactive C3 to C3b is not as efficient
in vitro as in vivo [30]. Mechanisms other than MAC formation may be elicited to enhance
the effect observed here. Previously, using a natural RNA aptamer construct we established
a system to induce phagocytosis of a molecular target by the macrophage-like THP-1 cells.
A similar set-up may be used to explore complement-dependent cell-mediated cytotoxicity
(CDCC). However, the interaction of macrophages and tumor cells is very complex. Tumorinfiltrating macrophages may be induced to become tumor-associated macrophages (TAM)
to assist tumor progression [31,32]. Therefore, implementation of macrophage-focused
strategies in cancer treatment requires more information and consideration in the future.
Regarding the approach to combining aptamers and complement proteins to elicit
MAC formation, it is informative to compare our work with another attempt. Bruno [33]
used a biotin-conjugated DNA aptamer against MUC1 and a streptavidin-C1q fusion
protein to trigger the classical complement pathway, and achieved a moderate killing effect
on breast cancer cells. Our approach has two critical advantages. First, in addition to the
MUC1 aptamer, Bruno’s strategy requires delivery of an amount of exogenous tagged C1q
significantly exceeding endogenous C1q, which is difficult to achieve in a living organism.
In contrast, our approach does not involve exposure to exogenous proteins. Second, we
utilize the aptamer to commandeer endogenous C3 and its derivatives rather than C1q; C3
is the point of convergence for all three complement pathways while C1q functions only
as the starting point of the classical pathway. This may at least partially account for the
different efficiency of the two methods in similar cell-based assays.
It is interesting to notice the feasibility of using our aptamers and their derivatives
in vivo in rodents or humans for eventual therapeutic applications. We already used
mouse serum as the source of effectors, which makes future testing of our construct
feasible in rodent models. The ability of aptamers to penetrate the tumor tissue has
been well documented [34,35], and uptake of aptamers can be monitored by PCR or a
fluorescent marker [36]. We should be able to use EGFR+ and EGFR- cancer cells grown
as xenografts in nude mice to directly extend the in vitro data, and expand the work
into more clinically relevant patient-derived xenografts (PDX) [37] in severe combined
immunodeficient (SCID) mice, which lack B- and T-cell function but retain innate immunity
including the complement system [38]. Nude mouse models were used to demonstrate
that a combined regimen of mAb and β-glucan induced regression of xenografted human
neuroblastoma cells [39], indicating that sufficient iC3b is present to activate its receptor
and trigger tumor cell killing. Some EGFR+ TNBC cells display or develop resistance to
EGFR inhibitors [19,20], and clinical trials of small molecule EGFR inhibitors in TNBC have
been disappointing [21]. However, our strategy could be more effective in the induction of
tumor regression, as it causes direct cell damage rather than solely targeting EGFR kinase
activity, and should work in resistant tumors that retain membrane EGFR.
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Appendix A. Isolation of RNase-Resistant Aptamers for C3 and Its Derivatives
Appendix A.1. Nucleic Acid Sequences
AptC3-1 core sequence used in doped pools:
50 -GCUAGAAGAAUAUGACGGAUUGACCGUAUCAGGGUAGC-30
Constant regions in the context of full-length pool sequences:
50 -GGGAGAAUUCAACUGCCAUCUA-(N55
GGACUCGGU-30

or

N58)-GACUACAAGCUUCU

Oligos used to construct the DNA pool:
Oligo-1:
50 -ACCGAGTCCAGAAGCTTGTAGTC-(N55)-TAGATGGCAGTTGA
ATTCTCCC-30
Oligo-2: 50 -GTAATACGACTCACTATAGGGAGAATTCAACTGCCATC-30
Oligo-3: 50 -ACCGAGTCCAGAAGCTTGTAGT-30
Oligo-4:
50 -ACCGAGTCCAGAAGCTTGTAGT-(GCTACCCTGATACGGTCAA
TCCGTCATATTCTTCTAGC—30% doped)-(N20)-TAGATGGCAGTTGAATT CTC-30
Oligo-5:
50 -ACCGAGTCCAGAAGCTTGTAGT-(N20)-(GCTACCCTGATACGG
TCAATCCGTCATATTCTTCTAGC—30% doped)-TAGATGGCAGTTGAATT CTC-30
Aptamer-specific complementary oligos for Hybridase treatment:
Oligo-6:
Oligo-7:
Oligo-8:
Oligo-9:

50 -CTGGTACTTTGCTTTCCTC-30
50 -GCTTGCCATGCGTAGGAGGCC-30
50 -CGCTGAACGCGGCCGAGG-30
50 -GCACTGGTACTTTGCTATCCTC-30

Appendix A.2. In Vitro Selection
Pool construction: For each pool, two DNA oligos, a long oligo (oligo-1/oligo-4/oligo5) and the short oligo-2 were mixed at a ratio of 1:6 (0.25 µM:1.5 µM) and extended by Taq
polymerase. Two rounds of primer extension were performed in a total volume of 12 mL,
containing 1.5 M betaine, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2 , 0.2 mM
each dNTP and 10 units/mL Taq DNA polymerase. Twelve mL of the above product was
amplified for another 3 PCR cycles in a total volume of 48 mL, after adding 36 mL of new
reagents (1.5 M betaine, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2 , 0.2 mM each
dNTP, 1 µM oligo-2, 1 µM oligo-3, 10 units/mL Taq DNA polymerase). The PCR-amplified
double strand DNA template was used in transcription reactions using the DuraScribe
T7 transcription kit. For each template, approximately 425 µg of DNA was used for the
transcription reaction in a total volume of 2.5 mL. 20 -fluoro pyrimidine (20 -F Py) RNA was
prepared according to the kit manufacturer’s recommendations. The total amount of RNA
produced was about 5 mg.
Selection and amplification: These steps were carried out as previously described [12]
with minor modifications. In some cycles negative selection against 5 µg C3 was performed
to enrich aptamers specific for C3b or iC3b. Hybridase treatment was performed according
to a previously described protocol [13]. We reduced levels of four known aptamers (AptC3I through IV) in the mixed RNA pool by incubating the pool RNA with DNA oligos
complementary to the variable region of those four aptamers and treating with Hybridase
to remove DNA-RNA hybrids. About 15 pmol of RNA and 1.5 pmol of each DNA oligo
(oligo-6, -7, -8, and -9) were used.
Appendix A.3. Results
We performed three in vitro selection experiments and generated a set of aptamers in
the form of RNase resistant 20 -F Py RNA. First, using a sequence pool with a 55-nt variable
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region, we performed 9 cycles of selection. As before, the target was purified C3 protein.
This experiment yielded 3 enriched sequences later proved to be aptamers. They were
named AptC3-I, AptC3-II, and AptC3-III (Table A1).
Table A1. Selection and characterization of aptamers for C3 and its derivatives.
SELEX Exp.
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Target
Protein

#1

Un-doped
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#2
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iC3b

#3
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Affinity to
C3 **
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C3b **

Affinity to
iC3b **

AptC3-I (18/96)
AptC3-II * (17/96)
AptC3-III * (5/96)
AptC3-IV (14/41)
AptC3-II * (2/41)
AptC3-V (9/90)
AptC3-VI (5/90)
AptC3-III * (3/90)

++
++
++++

+++
++
++++

+++
++
++++

+

++++

+++

++
+

+++
++++

++
+

* These aptamers compete with each other in binding assays. ** Four “+” signs indicate a Kd of ~15 nM; one “+”
sign indicates a Kd of ~50 nM.

C3-derived opsonins are a group of proteolytic products of C3. C3 was used in previous selections to avoid isolating inhibitory aptamers for C3b/iC3b, and the natural RNA
aptamer AptC3-1 was able to recognize C3b and iC3b with a slightly weaker affinity [12].
To utilize this information, we synthesized two “doped” pools based on the sequence of
the previously isolated AptC3-1: a 38-nt segment was doped at 30%, and on either its 50
(pool I) or 30 side (pool II) a 20-nt unbiased random segment was added to create a 58-nt
variable region. These two pools were mixed in a 1:1 ratio and used in a second in vitro
selection experiment with iC3b as the target. We also performed one negative selection
against C3 to promote selection of aptamers for its proteolytic products rather than intact
C3. After 12 cycles, we isolated one new aptamer named AptC3-IV. AptC3-II were also
present in this selected pool (Table A1).
To isolate additional aptamers we performed a third experiment for which the starting
material was the RNA pools that had undergone one cycle of selection and amplification in
the two experiments described above. A 1:1 mixture of these two pools was selected and
amplified for 15 cycles with iC3b as the target. The first, second and eleventh generation
were treated with Hybridase and a set of oligos to remove the 4 previously isolated aptamers.
Negative selection against C3 was performed in each cycle. In this experiment we isolated
three aptamer sequences. Two of them were novel, and were designated AptC3-V and
AptC3-VI. The third had already been isolated in the first experiment as AptC3-III. As
shown in Table A1, we isolated six aptamers in total for C3 and its derivatives in the form
of 20 -F Py RNA.
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